April 15, 2020

  • Depo-subQ Provera 104 (medroxyprogesterone acetate) – for birth control and endometriosis
  • Geodon (ziprasidone hydrochloride) oral suspension – for schizophrenia and bipolar disorder
  • Nymalize (nimodipine) – for brain hemorrhage

Adverse reactions or quality problems experienced with the use of a recalled product can be reported to the FDA’s MedWatch Adverse Event Reporting Program online, by mail, or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.

June 18, 2020

Crysvita Receives New Indication to Treat Rare Bone Disease

Read More
June 17, 2020

Keytruda Granted New Indication to Treat Cancer Based on Biomarkers, Regardless of Tumor Type

Read More
June 16, 2020

Mylotarg Receives Expanded Indication for Leukemia

Read More
June 16, 2020

Cosentyx Receives New Indication for Axial Spondyloarthritis

Read More